CureVac Announces Financial Results and Business Updates for the Third Quarter and First Nine Months of 2020
Operating result
Operating loss was €36.8 million and €63.2 million for the three and nine months ended September 30, 2020, respectively, representing an increase of €17.6 million and a decrease of €1.2 million, or an increase of 92% and a decrease of 2%, from -€19.2 million and -€64.4 million for the same periods in 2019, respectively.
COVID-19 prophylactic vaccine candidate: CVnCoV on track for advanced clinical testing
Interim Phase 1 data showed generally good tolerability for CVnCoV and strong antibody responses in addition to first indication of T cell activation
Stability confirmed for at least three months at standard refrigerator temperature and for up to 24 hours at room temperature
Pivotal Phase 2b/3 to be initiated shortly with 12µg dose
Agreement with European Commission to supply 225 million doses of CVnCoV and an option for an additional 180 million doses
Building a strong European manufacturing network to supply up to 300 million doses by end of 2021 and up to 600 million doses by the end of 2022
Phase 1 results for oncology lead candidate, CV8102, confirm tolerability and responses in additional cancer indication
Financials: Cash position of €892 million as of September 30, 2020
1 % CAPITAL
Operating result
Operating loss was €36.8 million and €63.2 million for the three and nine months ended September 30, 2020, respectively, representing an increase of €17.6 million and a decrease of €1.2 million, or an increase of 92% and a decrease of 2%, from -€19.2 million and -€64.4 million for the same periods in 2019, respectively.
COVID-19 prophylactic vaccine candidate: CVnCoV on track for advanced clinical testing
Interim Phase 1 data showed generally good tolerability for CVnCoV and strong antibody responses in addition to first indication of T cell activation
Stability confirmed for at least three months at standard refrigerator temperature and for up to 24 hours at room temperature
Pivotal Phase 2b/3 to be initiated shortly with 12µg dose
Agreement with European Commission to supply 225 million doses of CVnCoV and an option for an additional 180 million doses
Building a strong European manufacturing network to supply up to 300 million doses by end of 2021 and up to 600 million doses by the end of 2022
Phase 1 results for oncology lead candidate, CV8102, confirm tolerability and responses in additional cancer indication
Financials: Cash position of €892 million as of September 30, 2020
1 % CAPITAL